The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | REGONEXT: 2L regorafenib in patients with unresectable HCC who have progressed on atezo-bev
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, discusses results from a Phase II investigator-initiated trial conducted in Korea which aimed to assess the efficacy and safety of second-line regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) who experienced progression on first-line atezolizumab-bevacizumab (atezo-bev) treatment. Results indicated a median progression-free survival (PFS) of 3.5 months, with an objective response rate (ORR) of 10.0% and a disease control rate (DCR) of 82.5%. Adverse events were manageable. The study supports regorafenib as a viable second-line therapy for uHCC after atezolizumab-bevacizumab failure. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
